Inspire Medical Systems, Inc.: directors' dealings · United States · SEC (Form 4)

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. is a United States medical technology company listed on the NYSE under the ticker INSP. The company is focused on the development and commercialization of minimally invasive solutions for obstructive sleep apnea (OSA), a large chronic condition that remains materially underdiagnosed and undertreated. Its core offering is the Inspire system, an implantable neurostimulation therapy designed for selected patients with moderate to severe OSA, offering an alternative to traditional positive airway pressure therapy. The company was founded in 2007 following a spin-out of technology and intellectual property from Medtronic. Its headquarters are in Minneapolis, Minnesota, which anchors the business in one of the key U.S. medtech hubs. From the outset, Inspire built its strategy around a combination of clinical evidence, physician adoption, reimbursement expansion, and product iteration rather than broad device diversification. Operationally, Inspire Medical Systems is primarily engaged in the design, development, manufacturing, and commercialization of its proprietary OSA therapy, along with the associated clinical and patient-support ecosystem. The business has evolved through multiple product generations, and recent company communications highlight the rollout of Inspire V as the fifth-generation platform. That transition is strategically important because it supports the company’s long-term installed base, clinical workflow, and reimbursement discussions. The model remains largely concentrated in a single therapy family, but it is differentiated by strong gross margins and recurring commercial momentum as more centers begin implanting the therapy. In competitive terms, Inspire holds a first-mover position. The company states that its system is the first FDA-approved neurostimulation technology for OSA, which gives it a meaningful regulatory and branding advantage. That said, the market is still highly dependent on reimbursement coverage, coding clarity, physician training, and sustained clinical outcomes. These factors can materially influence adoption rates and the pace of revenue scaling. Geographically, Inspire’s revenue base is still primarily U.S.-driven, though the company has been expanding internationally through selected markets and reimbursement pathways. Recent corporate updates have emphasized the U.S. launch of Inspire V, broader physician training, and continued progress on reimbursement infrastructure. In February 2026, the company reported full-year 2025 results and noted the completion of the Inspire V launch, along with 3.0T MRI compatibility approval and ongoing efforts to secure a separate CPT code to better support reimbursement. For investors, INSP represents a high-quality growth name in healthcare, with significant upside tied to therapy adoption, but also meaningful sensitivity to regulatory, payer, and execution risk.